<DOC>
	<DOCNO>NCT02750553</DOCNO>
	<brief_summary>This randomize , placebo-controlled , single &amp; multiple dose escalation study investigate safety , tolerability , pharmacokinetics pharmacodynamics SHR0534 . The study conduct start dose 5 mg follow dose escalation group 100 mg . Healthy Chinese subject randomize cohort receive study drug placebo .</brief_summary>
	<brief_title>A Phase 1 , Randomized , Placebo-controlled , Single &amp; Multiple Dose Escalation Study Investigate Safety , Pharmacokinetics , Pharmacodynamics SHR0534 Healthy Chinese Volunteers</brief_title>
	<detailed_description />
	<criteria>Must BMI 18 24.9 kg/m2 , inclusive ; Clinical laboratory test ( i.e.blood chemistry , urinalysis ) must within normal reference range clinically acceptable determined investigator ; Subjects must free clinically significant disease base medical history , physical examination and/or investigator 's judgment ; Winthout bad habit , include smoking , drink others ; Negative Urine serum pregnancy test woman , female subject childbearing potential male subject must willing use acceptable method birth control duration study continue 90 day discontinue treatment investigational ; Subject must able understand information associate study , willing provide write informed consent . Clinically relevant abnormality physical examination , laboratory value , vital sign ECG finding screen , judged Investigator ; History surgery major trauma within 12 week study entry , surgery plan study ; History hypersensitivity SHR0534 component ; Any condition know interfere absorption , distribution , metabolism , excretion drug , history severe unconsciousness hypoglycemia judge researcher ; History liver disease . Those Alanine aminotransferase ( ALT ) Aspertate aminotransferase ( AST ) &gt; 1.5 time upper limit normal must exclude ; Severe infection , trauma major surgery 4 week screen ; Congestive heart failure serious heart lung disease need medication ; Have positive test Screening human immunodeficiency virus ( HIV ) , hepatitis B surface antigen ( HBsAg ) , hepatitis C virus antibody ( HCVAb ) ; Positive nicotine screen test , refrain smoking ; Urine drug screen test positive ethanol , cocaine , tetrahydrocannabinol ( THC ) , barbiturates , amphetamine , benzodiazepine , opiate ; Subject refrain smoking , eat and/or drink contain xanthine/caffeine , strenuous exercise , others affect drug absorption , distribution , metabolism excretion within 2 day study drug administration ; Have use drug substance ( include herbal supplement ) know inhibit induce cytochrome ( CYP ) P450 enzymes include CYP3A4 , CYP2C8 CYP2C9 within 28 day prior first dose throughout study ; Use prescription drug Chinese herbal medicine within 4 week randomization , use non prescription drug food supplement ( vitamin , etc . ) within 2 week randomization ; Participated drug clinical trial within 3 month , blood donation/loss â‰¥500 mL within 4 week randomization ; Female subject childbearing potential use acceptable method birth control , pregnant planning pregnancy , breastfeeding , male subject use acceptable method birth control , within six month randomization ; Subject unsuitable inclusion study opinion investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>